Teflutixol (Lu 10-022): a new thioxanthene derivative with antipsychotic properties. A pilot study.
A new thioxanthene derivative, teflutixol (Lu 10-022) has been administered for 4 weeks to 21 patients [12 schizophrenics, 6 patients with obsessive, compulsive neurosis (OCN), 2 patients with affective psychosis (AP), and one patient with paranoic reactions (PR)]. The maximum daily dose varied between 0.5 mg and 4 mg administered once in the morning. Fifteen of the patients received 1 mg or less daily. Based upon weekly assessments by the BPRS as well as a global evaluation all 4 groups showed a clear amelioration of the scores, and for both the schizophrenics and the patients with OCN this was highly significant [student's t (p less than 0.001)].
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D012559:Schizophrenia / Q000188:drug therapy; D013892:Thioxanthenes / Q000008:administration & dosage*
D014150:Antipsychotic Agents; D013892:Thioxanthenes; C013277:teflutixol